{"id":"kct-0809","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, KCT-0809 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"KCT-0809 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:02:59.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02503176","phase":"PHASE3","title":"An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye With Sjögren's Syndrome","enrollment":""},{"nctId":"NCT02503163","phase":"PHASE3","title":"A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye With Sjögren's Syndrome","enrollment":""},{"nctId":"NCT02503189","phase":"PHASE3","title":"A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye With Sjögren's Syndrome","enrollment":""},{"nctId":"NCT01890941","phase":"PHASE2","title":"A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye Syndromes","enrollment":""},{"nctId":"NCT01692145","phase":"PHASE2","title":"A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye Syndromes","enrollment":""},{"nctId":"NCT01427816","phase":"PHASE2","title":"A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye Syndromes","enrollment":180},{"nctId":"NCT01211951","phase":"PHASE2","title":"A Study of KCT-0809 in Patients With Dry Eye Syndromes","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Dry Eye Syndromes","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"KCT-0809","genericName":"KCT-0809","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KCT-0809 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}